Search

Displaying results 3591 - 3600 of 10000 in total
  1. Drug

    Depemokimab

    go.drugbank.com/drugs/DB18846
    ApprovedInvestigational

    [A275338] Approved by the FDA on December 16, 2025, depemokimab is indicated as an add-on maintenance treatment for severe asthma characterized by an eosinophilic phenotype in adult and paediatric patients … [A275338] Depemokimab blocks interleukin-5 (IL-5), a key cytokine that regulates eosinophil maturation, survival, and recruitment.

    Synonyms: Immunoglobulin g1, anti-(human interleukin 5) (human-mus musculus monoclonal gsk3511294 .gamma.1-chain), disulfide with human-mus musculus monoclonal gsk3511294 .kappa.-chain, dimerCategories: Interleukin-5 Antagonist
  2. Drug

    Bexotegrast

    go.drugbank.com/drugs/DB16515
    Investigational

    The compound was granted orphan drug designation by the US FDA in August 2018 for treatment of IPF, and Pliant Therapeutics recently raised $100 million in Series C financing to support further clinical … Phase 2a studies are currently evaluating PLN-74809 safety and efficacy for participants with IPF (NCT04396756)across 10 participating countries[L31703], and for participants with PSC (NCT04480840).

  3. Drug

    RPI-MN

    go.drugbank.com/drugs/DB17957
    Experimental

    RPI-MN is a detoxified or chemically modified alpha-cobratoxin with antiviral properties. … [A260132] Being developed by Nutra Pharma under the trade name PEPTERON, it is being investigated for the treatment of neurological and immune disorders.[L47107]

    Synonyms: RPI-MN
  4. Drug

    Omacetaxine mepesuccinate

    go.drugbank.com/drugs/DB04865
    ApprovedInvestigationalWithdrawn

    used to treat accelerated or chronic phase CML. … Most recently, in October 2012, omacetaxine mepesuccinate was marketed under the brand name Synribo and FDA approved for patients who are intolerant and/or resistant to two or more tyrosine kinase inhibitors

    Synonyms: (2'R,3S,4S,5R)-(−)-homoharringtonine
  5. Drug

    Gancotamab

    go.drugbank.com/drugs/DB14784
    Investigational

    Gancotamab is under investigation in clinical trial NCT02213744 (MM-302 Plus Trastuzumab vs.

  6. Drug

    Belapectin

    go.drugbank.com/drugs/DB15125
    Investigational

    Belapectin is under investigation in clinical trial NCT02575404 (GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients).

  7. Drug

    Avatrombopag

    go.drugbank.com/drugs/DB11995
    ApprovedInvestigational

    a procedure by increasing platelet counts to the optimal level ≥50,000 per microliter. … [F95] Avatrombopag was first approved by the FDA in May 2018 for use in adults with chronic liver disease who are scheduled to undergo a procedure.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 Inducers
  8. Drug

    Fidanacogene elaparvovec

    go.drugbank.com/drugs/DB16783
    ApprovedInvestigational

    [L46691] Hemophilia B is a rare X-linked genetic disorder characterized by abnormal coagulation due to dysfunctional coagulation factor IX with a male incidence estimated to be 1 in 30,000 male births … from week 12 to month 15 compared to an ABR of 4.43 for the pre-treatment period.

  9. Drug

    Sutimlimab

    go.drugbank.com/drugs/DB14996
    ApprovedInvestigational

    [A245159,L40114] In approximately 90% of cases, patients develop immunoglobulin M (IgM) autoantibodies towards the I antigen on erythrocytes - these antibodies react optimally at 4°C and are therefore … In addition to non-pharmacological strategies, such as counseling patients to keep warm and the use of red blood cell transfusions, approximately 70% of patients require pharmacological treatment.

  10. Drug

    Dioxybenzone

    go.drugbank.com/drugs/DB11221
    ApprovedWithdrawn

    Dioxybenzone is an approved sunscreen ingredient in concentrations up to 3% [L2525].